Sustained Release of Minocycline Hydrochloride from Biomaterials
Zhiling Zhang1, Yinghui Zhong1* and Hai-Feng Ji2*
1School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, USA
2Department of Chemistry, Drexel University, Philadelphia, USA
- *Corresponding Author:
- Yinghui Zhong
School of Biomedical Engineering
Science and Health Systems
Drexel University, Philadelphia, USA
E-mail: [email protected]
- Hai-Feng Ji
Department of Chemistry
Drexel University, Philadelphia, USA
E-mail: [email protected]
Received date: April 27, 2016; Accessed date: April 28, 2016; Published date: May 06, 2016
Citation: Zhang Z, Zhong Y, Ji HF (2016) Sustained Release of Minocycline Hydrochloride from Biomaterials. J Nanomedine Biotherapeutic Discov 6:e142. doi:10.4172/2155-983X.1000e142
Copyright: © 2016 Zhang Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Nanomedicine & Biotherapeutic Discovery
Minocycline Hydrochloride (MH) is a second-generation, semisynthetic tetracycline antibiotic derivative (Figure 1). It blocks the association of aminoacyl-tRNA with the bacterial ribosome and thus inhibits the bacterial protein synthesis. Independent of its antibacterial property, MH also exhibits potent anti-inflammatory effects, which makes it a promising drug candidate to combat implant-associated infection and inflammation [1-5]. In addition, MH can inhibit smooth muscle cell proliferation and neointimal hyperplasia after arterial injury  and reduce tumor expansion and migration . MH also demonstrated cytoprotective properties in the cardiovascular, renal, and Central Nervous Systems (CNS) via its anti-oxidative and antiapoptotic properties. MH protects neurons from oxidative stress by scavenging free radicals , preventing excitotoxicity by diminishing Ca2+ influx and uptake , and suppressing activation of caspases . As a result, MH has been shown to provide neuroprotection in a variety of Central Nervous System (CNS) injuries and neurodegenerative diseases, such as Spinal Cord Injury (SCI) , traumatic brain injury , stroke , Parkinson’s disease , Alzheimer’s disease , multiple sclerosis , and amyotrophic lateral sclerosis , etc.
Figure 1: Chemical structure of MH.
However, many of these diseases require continuous high concentrations of MH at the injury site for effective treatment. For example, to inhibit tumor growth in mice, the maintenance of 60-120 mg/kg MH is needed for 4 weeks , which is much higher than the standard human dose of 3 mg/kg . Systemic administration of high doses of MH for extended period of time has been shown to cause side effect, such as morbidity, liver toxicity, and even death in experimental animals. Thus, localized delivery of MH is needed to deliver high concentrations of MH to the injury sites continuously without causing significant side effects.
The challenges related to drug delivery of MH is that MH is a small molecule (Mw = 494 Da) with high water solubility, so that MH was generally released quickly from current hydrophilic drug delivery systems , such as MH loaded in Poly(Vinyl Alcohol) (PVA) hydrogel with chitosan . As a result, current drug delivery systems are not ideal for localized delivery of high concentration of MH over an extended period of time.
There is a need to develop drug delivery mechanisms for sustained and controlled delivery of MH. Several strategies have been implemented and are still under investigation.
1. Hydrophobic polymers have been used to increase the duration of MH release. As one example, Poly (Lactic-co-Glycolic Acid) (PLGA) nanoparticles  demonstrated sustained release of MH, although the loading efficiency of MH in the PLGA particles was low (less than 1%). Adding dextran sulfate (DS) into the system could reduce the solubility of MH so that the diffusion of MH into external medium would be slowed down to improve the encapsulation of MH in polymers or nanoparticles. The results showed that addition of DS solution increased the loading efficiency 1.92% .
2. MH can also chelate multivalent metal ions such as Ca2+ and Mg2+ to form chelate complexes without affecting its biological activities . For example, MH-Ca2+ chelate was encapsulated into polyion complex micelle of carboxymethyldextran-blockpoly( ethylene glycol) (CMD-PEG) so that the positively charged MHCa2+ chelate could be entrapped in an negatively charged micelle for drug delivery . Drug loading efficiency in this system is high (50%). However, MH release from the PIC micelles only lasted for 24 hours, possibly because the electrostatic interaction is not strong enough for supporting sustained drug release.
3. Metal ion-assisted complex formation. Both DS and MH have high binding affinity for metal ions (M+) such as Ca2+ and Mg2+. When mixing the three components together, an insoluble complex of DS-M2+-MH can be obtained. In this system metal ions play a critical role in complex formation and MH release by binding to both DS and MH molecules simultaneously. The metal ion-mediated interaction is strong but reversible, which enables high drug loading efficiency (45%) and sustained release of MH .
4. MH-loaded complexes may not stay in local injured/diseased site and diffuse away over time. In order to selectively deliver the MHcontaining complexes at the injury site, it is preferable to encapsulate the complexes into injectable hydrogel [25,26]. The injectable properties enable the hydrogel to be delivered at the injury site in human body with minimal surgical wounds. Hydrogels are ideal candidates to load and deliver drugs due to its porous and biocompatible nature. However, since the pore size of hydrogels is usually too large to slow down the diffusion of drugs, drug deliver systems are generally incorporated into the injectable hydrogels simply by mixing before injection, and will be immobilized at certain positions in the body for localized drug delivery.
Injectable hydrogels can be formed by different mechanisms, including chemical crosslinking and physically crosslinking. For the chemical crosslinking, since the exposure of drugs to free radicals potentially affects drug activity , initiator-free approach to prepare chemical crosslinking hydrogel would be a better choice [28-32]. Besides chemically crosslinking hydrogel, physically crosslinking hydrogels are also popular for drug delivery. Comparing to chemical crosslinking, physical crosslinking avoids the biocompatibility issue of residue initiators or monomers. The driving force of physical crosslinking is usually the phase transition on a change of environmental conditions, such as salt, temperature and etc [33-36].
This editorial briefly summarized several biomaterial-based drug delivery systems for sustained release of MH for biomedical applications. These methods may be used for drug delivery of other drug molecules. Work in delivery is a strong component of this journal and manuscripts in this area are strongly encouraged to submit.
- Garrido-Mesa N, Zarzuelo A,Galvez J (2013) Minocycline: far beyond an antibiotic. Br J Pharmacol 169: 337-352.
- Vandekerckhove BNA, Quirynen M,SteenbergheVD (1998) The use of locally-delivered minocycline in the treatment of chronic periodontitis. A review of the literature. J ClinPeriodontol25: 964-968.
- Humbert P, Treffel P, Chapuis JF, Buchet S, Derancourt C, et al.(1991) The tetracyclinesindermatology.J Am Acad Dermatol 25: 691-697.
- Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C,Dijkmans BA (1994) Minocycline in active rheumatoid arthritis. A double-blind, placebo- controlled trial. Arthritis Rheum 37: 629-636.
- Nieman GF,Zerler BR (2001) A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 8: 317-325.
- Pinney SP, Chen HJ, Liang D, Wang X, Schwartz A, et al.(2003) Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J CardiovascPharmacol 42: 469-476.
- Markovic DS, Vinnakota K, Rooijen NV, Kiwit J, Synowitz M, et al. (2011) Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain BehavImmun 25: 624-628.
- Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, et al. (2005) Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 94: 819-827.
- Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, et al. (2010) Mitochondria and calcium flux as targets of neuroprotection caused byminocycline incerebellargranulecells.BiochemPharmacol 79: 239-250.
- Mejia ROS, Ona VO, Li M,Friedlander RM (2001) Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48: 1393-1401.
- Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, et al. (2003) Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20: 1017-1027.
- Fagan SC, Cronic LE,Hess DC (2011) Minocycline Development for Acute Ischemic Stroke. Transl Stroke Res 2: 202-208.
- Quintero EM, Willis L, Singleton R, Harris N, Huang P, et al. (2006) Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res 1093: 198-207.
- Choi Y, Kim HS, Shin KY, Kim EM, Kim M, et al. (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32: 2393-2404.
- Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, et al. (2007) Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 25: 514-525.
- Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.
- Pourgholami MH, Ataie-Kachoie P, Badar S,Morris DL (2013) Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways. GynecolOncol 129: 113-119.
- Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, et al. (2004)Low doseintravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC neurology 4: 7.
- Jones DS, Lorimer CP, Mccoy CP, Gorman SP (2008) Characterization of the physicochemical, antimicrobial, and drug release properties of thermoresponsive hydrogel copolymers designed for medical device applications. Journal of Biomedical Materials Research Part B: Applied Biomaterials 85: 417-426.
- Sung JH, Hwang MR, Kim JO, Lee JH, Il Kim Y, et al. (2010) Gel characterisation and in vivo evaluation of minocycline-loaded wound dressing with enhanced wound healing using polyvinyl alcohol and chitosan. Int J Pharm 392: 232-240.
- Kashi TSJ, Eskandarion S, Esfandyari-Manesh M, Marashi SMA, Samadi N, et al. (2012) Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomedicine 7: 221.
- Lambs L, Brion M,Berthon G (1984). Metal ion-tetracycline interactions in biological fluids. Part 3. Formation of mixed-metal ternary complexes of tetracycline, oxytetracycline, doxycycline and minocycline with calcium and magnesium, and their involvement in the bioavailability of these antibiotics in blood plasma. Agents Actions 14: 743-750.
- Soliman GM, Choi AO, Maysinger D,Winnik FM (2010) Minocycline BlockCopolymerMicellesandtheirAnti-InflammatoryEffectsonMicroglia. MacromolBiosci10: 278-288.
- Zhang Z, Wang Z, Nong J, Nix CA, Ji HF, et al. (2015) Metal ion-assisted self-assembly of complexes for controlled and sustained release of minocycline for biomedical applications. Biofabrication 7: 015006.
- Yu L,Ding J (2008) Injectable hydrogels as unique biomedical materials. ChemSoc Rev 37: 1473-1481.
- Pakulska MM, Ballios BG,Shoichet MS (2012) Injectable hydrogels for central nervous system therapy. Biomed Mater 7: 024101.
- Williams CG, Malik AN, Kim TK, Manson PN,Elisseeff JH (2005) Variable cytocompatibility of six cell lines with photoinitiators used for polymerizing hydrogels and cell encapsulation. Biomaterials 26: 1211-1218.
- Yeo Y, Ito T, Bellas E, Highley CB, Marini R,et al. (2007) In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg245: 819.
- Van De Wetering P, Metters AT, Schoenmakers RG,Hubbell JA (2005) Poly (ethylene glycol) hydrogels formed by conjugate addition withcontrollable swelling, degradation, and release of pharmaceutically active proteins. J Control Release102: 619-627.
- Elbert DL, Pratt AB, Lutolf MP, Halstenberg S,Hubbell JA (2001) Protein delivery from materials formed by self-selective conjugate addition reactions. J Control Release 76: 11-25.
- Jeon O, Ryu SH, Chung JH,Kim BS (2005) Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release 105: 249-259.
- Sakiyama-Elbert SE, Hubbell JA (2000) Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 65: 389-402.
- Kuo CK,Ma PX (2001)Ionicallycrosslinked alginate hydrogels as scaffolds for tissue engineering: part 1. Structure, gelation rate and mechanical properties. Biomaterials 22: 511-521.
- Xiong X, Tam K,Gan L (2006) Polymeric nanostructures for drug delivery applications based on Pluronic copolymer systems. J NanosciNanotechnol6: 2638-2650.
- Zhang L, Parsons DL, Navarre C,Kompella UB (2002) Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85: 73-81.
- Joosten E, Bar PR,Gispen W (1995) Collagen implants and cortico-spinal axonal growth after mid-thoracic spinal cord lesion in the adult rat. J Neurosci Res 41: 481-490.